Living with HIV? Speak out to Pharma!

UPCOMING CTAC PATIENT GROUP INPUT CONSULTATIONS

CTAC is calling for people living with HIV to take part in patient consultations so that they can have their voices heard by drug regulators. The first 20 attendees who complete a survey at the end of each session will recieve a $10 gift voucher.

WEDNESDAY 10TH JANUARY 2018, 2:00-3:00 EST:

NEW HIV MEDICATION DOLUTEGRAVIR / RILPIVIRINE  - REGISTER HERE.

This informative webinar, led by CTAC Policy Researcher Amanda Fletcher, will discuss the new two-drug regimen Dolutegravir / rilpivirine and its clinical trials.

Participants will need to log on to http://ctac.adobeconnect.com/dolutegravir-rilpivirine/ to take part. Audio for this webinar will play on your computer. For more information please contact This email address is being protected from spambots. You need JavaScript enabled to view it. or call 437 222 2822 ext. 234.

FRIDAY 12TH JANUARY 2018, 2:00-3:00 EST:

NEW HIV MEDICATION DARUNAVIR / COBICISTAT / EMTRICITABINE / TENOFOVIR ALAFENAMIDE - REGISTER HERE.

This informative webinar, led by CTAC Policy Researcher Antu Hossain, will discuss the new treatment Darunavir/cobicistat/ emtricitabine/tenofovir alafenamide and its clinical trials.

Participants will need to log on to http://ctac.adobeconnect.com/janssen/ to take part.

Audio for this webinar will play on your computer. 

For more information please contact This email address is being protected from spambots. You need JavaScript enabled to view it. or call 437 222 2822 ext. 232.